|Bid||2.54 x 1000|
|Ask||3.24 x 900|
|Day's Range||3.0200 - 3.2000|
|52 Week Range||2.2600 - 7.5000|
|Beta (3Y Monthly)||4.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.35|
NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The direct benefit for Applied Genetic Technologies Corporation (NASDAQ:AGTC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the Read More...
Applied Genetic Technologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Applied Genetic Technologies Corp (NASDAQ: AGTC ), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis ...
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 114.00% and 383.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alachua, Florida-based company said it had net income of 7 cents. The biotechnology company posted revenue of $14 million in the period. Applied Genetic Technologies shares have ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 08, 2018 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 01, 2018 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC ), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an ...
Warning! GuruFocus has detected 2 Warning Signs with AGTC. For the last quarter Applied Genetic Technologies Corp reported a revenue of $3.60 million, compared with the revenue of $8.39 million during the same period a year ago. The Applied Genetic Technologies Corp had an operating margin of -92.55%, compared with the operating margin of 4.82% a year before.
The Alachua, Florida-based company said it had a loss of 37 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Applied Genetic Tech (NASDAQ: AGTC ) announces its next round of earnings Monday, Sept. 10. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings, Revenue Based ...